185 related articles for article (PubMed ID: 28918602)
1. Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation.
Mizuno K; Dong M; Fukuda T; Chandra S; Mehta PA; McConnell S; Anaissie EJ; Vinks AA
Clin Pharmacokinet; 2018 May; 57(5):625-636. PubMed ID: 28918602
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy.
Wilhelm AJ; de Graaf P; Veldkamp AI; Janssen JJ; Huijgens PC; Swart EL
Br J Clin Pharmacol; 2012 Apr; 73(4):553-63. PubMed ID: 21988410
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy.
Nath CE; Shaw PJ; Trotman J; Zeng L; Duffull SB; Hegarty G; McLachlan AJ; Gurney H; Kerridge I; Kwan YL; Presgrave P; Tiley C; Joshua D; Earl J
Br J Clin Pharmacol; 2010 May; 69(5):484-97. PubMed ID: 20573084
[TBL] [Abstract][Full Text] [Related]
4. Oral mucositis in myeloma patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model.
Grazziutti ML; Dong L; Miceli MH; Krishna SG; Kiwan E; Syed N; Fassas A; van Rhee F; Klaus H; Barlogie B; Anaissie EJ
Bone Marrow Transplant; 2006 Oct; 38(7):501-6. PubMed ID: 16980998
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of High-Dose Propylene Glycol-Free Melphalan in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation.
Dhakal B; D'Souza A; Lakshman A; Hamadani M; Chhabra S; Thompson R; Shah N; Pasquini M; Hari P
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1610-1614. PubMed ID: 29751116
[TBL] [Abstract][Full Text] [Related]
6. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study.
Tricot G; Alberts DS; Johnson C; Roe DJ; Dorr RT; Bracy D; Vesole DH; Jagannath S; Meyers R; Barlogie B
Clin Cancer Res; 1996 Jun; 2(6):947-52. PubMed ID: 9816255
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients.
Willcox A; Wong E; Nath C; Janson B; Harrison SJ; Hoyt R; Bajel A; Shaw P; Ritchie D; Grigg A
Ann Hematol; 2018 Dec; 97(12):2509-2518. PubMed ID: 30051172
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a Test Dose Strategy for Pharmacokinetically-Guided Busulfan Dosing for Hematopoietic Stem Cell Transplantation.
Davis JM; Ivanova A; Chung Y; Shaw JR; Rao KV; Ptachcinski JR; Sharf AA; Serody JS; Armistead PM; Wood WA; Coghill JM; Jamieson KJ; Vincent BG; Riches ML; Shea TC; Alexander MD
Biol Blood Marrow Transplant; 2019 Feb; 25(2):391-397. PubMed ID: 30244102
[TBL] [Abstract][Full Text] [Related]
9. Development of a pharmacokinetic and Bayesian optimal sampling model for individualization of oral busulfan in hematopoietic stem cell transplantation.
Bullock JM; Smith PF; Booker BM; Loughner J; Capozzi D; McCarthy PL; Shaw LM
Ther Drug Monit; 2006 Feb; 28(1):62-6. PubMed ID: 16418695
[TBL] [Abstract][Full Text] [Related]
10. Addressing the questions of tomorrow: melphalan and new combinations as conditioning regimens before autologous hematopoietic progenitor cell transplantation in multiple myeloma.
Martino M; Olivieri A; Offidani M; Vigna E; Moscato T; Fedele R; Montanari M; Console G; Gentile M; Messina G; Irrera G; Morabito F
Expert Opin Investig Drugs; 2013 May; 22(5):619-34. PubMed ID: 23550793
[TBL] [Abstract][Full Text] [Related]
11. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
[TBL] [Abstract][Full Text] [Related]
12. Icing oral mucositis: Oral cryotherapy in multiple myeloma patients undergoing autologous hematopoietic stem cell transplant.
Chen J; Seabrook J; Fulford A; Rajakumar I
J Oncol Pharm Pract; 2017 Mar; 23(2):116-120. PubMed ID: 26684614
[TBL] [Abstract][Full Text] [Related]
13. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing.
Bartelink IH; Boelens JJ; Bredius RG; Egberts AC; Wang C; Bierings MB; Shaw PJ; Nath CE; Hempel G; Zwaveling J; Danhof M; Knibbe CA
Clin Pharmacokinet; 2012 May; 51(5):331-45. PubMed ID: 22455797
[TBL] [Abstract][Full Text] [Related]
14. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy--European Blood and Marrow Transplantation Mucositis Advisory Group.
Blijlevens N; Schwenkglenks M; Bacon P; D'Addio A; Einsele H; Maertens J; Niederwieser D; Rabitsch W; Roosaar A; Ruutu T; Schouten H; Stone R; Vokurka S; Quinn B; McCann S;
J Clin Oncol; 2008 Mar; 26(9):1519-25. PubMed ID: 18268357
[TBL] [Abstract][Full Text] [Related]
15. Usefulness and safety of oral cryotherapy in the prevention of oral mucositis after conditioning regimens with high-dose melphalan for autologous stem cell transplantation for lymphoma and myeloma.
Batlle M; Morgades M; Vives S; Ferrà C; Oriol A; Sancho JM; Xicoy B; Moreno M; Magallón L; Ribera JM
Eur J Haematol; 2014 Dec; 93(6):487-91. PubMed ID: 24889275
[TBL] [Abstract][Full Text] [Related]
16. Relationship between exposure to treosulfan and its monoepoxytransformer - An insight from population pharmacokinetic study in pediatric patients before hematopoietic stem cell transplantation.
Danielak D; Kasprzyk A; Wróbel T; Wachowiak J; Kałwak K; Główka F
Eur J Pharm Sci; 2018 Jul; 120():1-9. PubMed ID: 29705215
[TBL] [Abstract][Full Text] [Related]
17. A Phase IIb, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation.
Hari P; Aljitawi OS; Arce-Lara C; Nath R; Callander N; Bhat G; Allen LF; Stockerl-Goldstein K
Biol Blood Marrow Transplant; 2015 Dec; 21(12):2100-2105. PubMed ID: 26327631
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetics of Melphalan in a Large Cohort of Autologous and Allogeneic Hematopoietic Cell Transplantation Recipients: Towards Individualized Dosing Regimens.
Shah GL; Boelens JJ; Carlow D; Lin A; Schofield R; Cruz Sitner N; Alperovich A; Ruiz J; Proli A; Dahi P; Tamari R; Giralt SA; Scordo M; Admiraal R
Clin Pharmacokinet; 2022 Apr; 61(4):553-563. PubMed ID: 34859337
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients.
Nath CE; Shaw PJ; Montgomery K; Earl JW
Br J Clin Pharmacol; 2007 Aug; 64(2):151-64. PubMed ID: 17324241
[TBL] [Abstract][Full Text] [Related]
20. Easy-to-use, accurate and flexible individualized Bayesian limited sampling method without fixed time points for ciclosporin monitoring after liver transplantation.
Langers P; Cremers SC; den Hartigh J; Rijnbeek EM; Ringers J; Lamers CB; van Hoek B
Aliment Pharmacol Ther; 2005 Mar; 21(5):549-57. PubMed ID: 15740538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]